Wugen, Inc.
allogeneic T-cell immunotherapies for cancer treatment
- Sector
- Biotech
- Headquarters
- St. Louis, MO
- Founded
- 2018
- Latest Form D
- $109M, Sep 2025
- Total capital
- $245M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $245M
- 3 Form D · last Sep 2025
- 14 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 35 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$109M
- Private capital raisedForm D · SEC · 2nd filing$37.2M
- Private capital raisedForm D · SEC · 1st filing$98.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Ayman KabakibiExecutive OfficerNamed in SEC Form D filings
- Bali K MuralidharDirectorNamed in SEC Form D filings
- Bosun HauDirectorNamed in SEC Form D filings
- Cherry ThomasExecutive OfficerNamed in SEC Form D filings
- Daniel M KempExecutive Officer, DirectorNamed in SEC Form D filings
- Drew DennisonDirectorNamed in SEC Form D filings
Show all 15 people
- Jan K DavidsonExecutive OfficerNamed in SEC Form D filings
- John P. McKearnDirectorNamed in SEC Form D filings
- Keith VendolaExecutive OfficerNamed in SEC Form D filings
- Kevin P LiDirectorNamed in SEC Form D filings
- Kumar SrinivasanExecutive Officer, DirectorNamed in SEC Form D filings
- Matthew CooperExecutive OfficerNamed in SEC Form D filings
- Natalie MountDirectorNamed in SEC Form D filings
- Niall O'DonnellDirectorNamed in SEC Form D filings
- Peter P. KienerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 35- PendingExpansion Of Memory Natural Killer CellsUSPTOApplication 18412163
- PendingCombination Cancer Therapy With Memory Nk Cells And Anti-cancer Bispecific MoleculesUSPTOApplication 18657954
- PendingHypoimmunogenic Cells Having Targeted Modifications In Mhc Class-i Genes And Methods Of UseUSPTOApplication 18509110
Show all 35 patent records
- Expansion Of Memory Natural Killer CellsNov 14, 2024 · Application 18412163Pending
- Combination Cancer Therapy With Memory Nk Cells And Anti-cancer Bispecific MoleculesOct 31, 2024 · Application 18657954Pending
- Hypoimmunogenic Cells Having Targeted Modifications In Mhc Class-i Genes And Methods Of UseJun 13, 2024 · Application 18509110Pending
- Generation Of CD3 Expressing Immune Cells For Use In Conjunction With CD3 Binding Bispecific Targeting AgentsMay 30, 2024 · Application 18501908Pending
- Polypeptides And Their Use In Treatment Of DiseaseMar 28, 2024 · Application 18447138Pending
- Chimeric Receptor Constructs For Nk CellsMar 7, 2024 · Application 18186133Pending
- Chimeric Antigen Receptors And Uses ThereofFeb 1, 2024 · Application 18484253Pending
- Hybrid Promoters, Vectors Containing Same And Methods Of UseOct 19, 2023 · Application 18188410Pending
- Compositions And Methods For Treatment Of CancerMay 14, 2020 · Application 16679127Pending
- Generation Of CD3 Expressing Nk Cells For Use In Conjunction With CD3 Binding Bispecific Targeting AgentsApplication 63422919Pending
- Expansion Of Memory Natural Killer CellsApplication PCTUS2022037178Pending
- Improved Chimeric Antigen Receptors And Uses ThereofApplication PCTUS2022071692Pending
- Hybrid Promoters, Vectors Containing Same And Methods Of UseApplication 63322384Pending
- Chimeric Receptor Constructs For Nk CellsApplication 63321359Pending
- Polypeptides And Their Use In Treatment Of DiseaseApplication PCTUS2022015980Pending
- Combination Cancer Therapy With Memory-nk Cells And Anti-cancer Monoclonal AntibodiesApplication 63277505Pending
- Chimeric Antigen Receptor Cell TherapyApplication PCTUS2021057894Pending
- Expansion Of Memory Natural Killer CellsApplication 63222306Pending
- Chimeric Antigen Receptors And Uses ThereofApplication 63174321Pending
- Engineered Immune Cells For Adoptive Cell TherapyApplication PCTUS2021024958Pending
- Polymorphically Selective Polypeptides And Their Use In Treatment Of DiseaseApplication 63148012Pending
- Chimeric Antigen Receptor Cell TherapyApplication 63109076Pending
- Engineered Immune Cells For Adoptive Cell TherapyApplication 63001856Pending
- Compositions And Methods For Treatment Of CancerApplication PCTUS2019060644Pending
- Analogues Of Interleukin Proteins For In Vivo Expansion Of Car-bearing Immune Effector CellsApplication 62848962Pending
- Improved Methods Of Making Genome-edited Immune Effector CellsApplication PCTUS2025055654Pending
- Analogues Of Interleukin Proteins For In Vivo Expansion Of Car-bearing Immune Effector CellsApplication 62848975Pending
- Improved Methods Of Making Genome-edited Immune Effctor CellsApplication 63721220Pending
- Hypoimmunogenic Cells Having Targeted Modifications In Mhc Class-i Genes And Methods Of UseApplication PCTUS2023079665Pending
- Generation Of CD3 Expressing Immune Cells For Use In Conjunction With CD3 Binding Bispecific Targeting AgentsApplication PCTUS2023078745Pending
- Hybrid Promoters, Vectors Containing Same And Methods Of UseApplication PCTUS2023064828Pending
- Improved Chimeric Receptor Constructs For Nk CellsApplication PCTUS2023064666Pending
- Hypoimmunogenic Cells Having Targeted Modifications In Mhc Class-i Genes And Methods Of UseApplication 63425272Pending
- Combination Cancer Therapy With Memory Nk Cells And Anti-cancer Bispecific MoleculesApplication PCTUS2022079528Pending
- Generation Of CD3 Expressing Immune Cells For Use In Conjunction With CD3 Binding Bispecific Targeting AgentsApplication 63424120Pending
Related companies, and why
- Noumea Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- I2Pure Corp.Similar federal contract value in Biotech · null in contracts
- NK-One Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- TEMPRIAN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Pike Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- NKore Biotherapeutics, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .